Q1 2023
Released May 11, 2023, after the close
10-Q filed May 11, 2023, 41 days after period end · 0000950170-23-021374
Q1 2023 · 10-Q
Revenue$250.00K$250.00K — vs Q1 2022no prior Q4 2022 on file
Net Income-$2.34M-$2.34M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$8.13-$8.13 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$2,529,000N/M
Operating Cash Flow-$3,526,000N/M
Margins · derived
Operating margin-1011.6%
Net margin-936.0%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $250.00K | $0.00 | — | $6.02K |
| Net Income | -$2.34M | -$4.21M | -$4.03M | -$2.38M |
| EPS Diluted | -$8.13 | -$12.96 | -$0.79 | -$5.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palisade Bio, Inc. · CIK 1357459 · Engraved from SEC EDGAR